billHR6624Event Wednesday, April 22, 2026Analyzed

Biological Intellectual Property Protection Act of 2025

Neutral
Impact4/10

Summary

The Biological Intellectual Property Protection Act of 2025 (HR6624) has been ordered to be reported out of the House Foreign Affairs Committee, indicating progress towards a floor vote. This bill aims to restrict the export of U.S. intellectual property and sensitive information related to synthetic biology to foreign entities of concern, specifically citing the People's Republic of China.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR6624 restricts export of U.S. synthetic biology IP to foreign entities of concern, primarily China.
  • 2.The bill has advanced out of the House Foreign Affairs Committee and awaits a full House vote.
  • 3.No direct funding is authorized or appropriated by this bill; its impact is regulatory.
  • 4.A companion bill (S3452) exists in the Senate, suggesting broader legislative support.

Market Implications

The Biological Intellectual Property Protection Act of 2025 (HR6624) introduces new regulatory hurdles for companies in the synthetic biology sector involved in international trade, particularly with China. While no specific tickers are named, companies engaged in synthetic biology research, development, and manufacturing that have significant intellectual property or export operations will need to assess their compliance strategies. The bill's advancement indicates a continued focus on national security and intellectual property protection within the U.S. legislative agenda, potentially influencing long-term investment and operational decisions in the Healthcare and Technology sectors related to biotechnology.

Full Analysis

HR6624, the Biological Intellectual Property Protection Act of 2025, was ordered to be reported in the Nature of a Substitute (Amended) by the House Committee on Foreign Affairs on April 22, 2026, with a vote of 30-14. This action moves the bill closer to a full House vote. The bill's primary objective is to restrict the export of U.S. intellectual property and sensitive information related to synthetic biology to foreign entities of concern, particularly the People's Republic of China, citing national security threats. This bill does not authorize or appropriate specific funding amounts. Its mechanism is regulatory, imposing restrictions on exports rather than providing direct financial incentives or disbursements. Therefore, there is no direct money trail in terms of government spending. The impact will be felt through compliance costs and potential market access limitations for companies operating in the synthetic biology sector that engage with foreign entities of concern. Structural winners are not explicitly defined by this bill, as it focuses on restrictions. However, U.S. companies in the synthetic biology sector that prioritize domestic markets or allied international partnerships may face fewer operational disruptions compared to those with significant ties to entities of concern. Companies involved in synthetic biology research and development, particularly those with valuable intellectual property, will need to adapt to new export control regulations. Since the bill does not name specific companies or provide funding, no specific tickers can be identified as direct beneficiaries or losers at this stage. The bill's focus on national security and intellectual property protection aligns with broader U.S. policy trends concerning strategic technologies. As of April 24, 2026, the bill has been reported out of committee and is awaiting floor action in the House. A companion bill, S3452, has been introduced in the Senate and referred to the Committee on Banking, Housing, and Urban Affairs, indicating bipartisan and bicameral interest in the issue. The next legislative step for HR6624 is a vote by the full House of Representatives.

Market Impact Score

4/10
Minimal ImpactModerateMajor Market Event

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.